Vitruvia Medical AG
- WKN: A2PDWF
- ISIN: CH0461931419
- Land: Schweiz
Nachricht vom 28.07.2021 | 10:00
Vitruvia Medical AG: Successful certification for the reprocessing of 'critical C' devices - Vitruvia Medical now also providing circular systems for highest risk-level medical devices
DGAP-News: Vitruvia Medical AG
/ Key word(s): Regulatory Approval/Product Launch
Successful certification for the reprocessing of "critical C" devices - Vitruvia Medical now also providing circular systems for highest risk-level medical devices
This means that Vitruvia Medical is now certified to reprocess all surgical instruments, including those classed at the highest "critical C" risk level. These include flexible endoscopes as well as all instruments and optics for robot-assisted surgery which are authorized for reprocessing by the manufacturer.
Reprocessing has to meet exceptionally high standards to ensure the highest level of patient safety, as well as the hygienic and functional safety of the reprocessed medical device. For this reason, the German Medical Devices Operator Ordinance (MPBetreibV) requires that facilities reprocessing "critical C" risk-level medical devices must have a quality management system that is certified in line with DIN EN ISO 13485 and takes the Robert Koch Institute's "KRINKO Recommendation" into account.
The Vitruvia Medical Group has opened a 2,000 sqm Circular Clinic Supply Center for robotic instruments in Schönebeck, near Magdeburg - the first in Europe. After two years of renovation and upgrades, hospital instruments are now being prepared for reuse here under cleanroom conditions. With this sustainable concept, hospitals save both investment and operating costs when using robot-assisted surgical systems and also avoid the potential underuse of their own circular systems.
Further information: www.vitruvia-med.com
|Company:||Vitruvia Medical AG|
|Phone:||+41 44 915 33 78|
|Listed:||Regulated Unofficial Market in Munich|
|EQS News ID:||1221995|
|End of News||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
01. Dezember 07:43 Heidelberger Druck: SAP-Kooperation, Klimaziele und SDAX-Aufstieg - ...
01. Dezember 08:09 Hoffnung für die Börse dank Impfstoff – „viele Gründe für Optimismus“
01. Dezember 08:37 Deutsche Bank: CEO positiv für 2022, aber...
01. Dezember 08:40 Twitter: Dorsey geht – Abwärtstrend bleibt
01. Dezember 08:45 Allzeithoch! Apple-Bullen lässt Omikron kalt
News im Fokus
Fresenius Medical Care AG & Co. KGaA passt Besetzung des Vorstands an neues Betriebsmodell an
01. Dezember 2021, 08:30
Capital Markets Day
08. Dezember 2021
Original-Research: Li-Metal Corp. (von Sphene Capital GmbH): Buy
01. Dezember 2021